VVOS Insider Trading Activity and SEC Form 4 Filings
VVOS insider trading summary
Over the past 12 months, insiders at Vivos Therapeutics, Inc. (VVOS) reported 4 open-market purchases worth $3.6M by 2 insiders and no sales on SEC Form 4. Net insider buying was $3.6M.
Latest VVOS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 31, 2026 | Michael C Skaff | Insider | Buy | $1.4M (1,044,777 @ $1.34) |
| Mar 31, 2026 | V-Co Investors 3 LLC | Insider | Buy | $414K (308,848 @ $1.34) |
| Mar 31, 2026 | Michael C Skaff | Insider | Buy | $414K (308,848 @ $1.34) |
| Mar 31, 2026 | V-Co Investors 3 LLC | Insider | Buy | $1.4M (1,044,777 @ $1.34) |
| Jun 20, 2023 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | $7K (14,000 @ $0.53) |
| Jun 16, 2023 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | $3K (5,000 @ $0.53) |
| Jun 16, 2023 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | $5K (10,000 @ $0.54) |
| Jun 15, 2023 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | $11 (21 @ $0.50) |
| Jun 14, 2023 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | $5K (10,000 @ $0.49) |
| Dec 23, 2022 | Ronald Kirk Huntsman | Chief Executive Officer | Buy | $10K (20,000 @ $0.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.